NSAIDs and cardiovascular risk

Impact of NSAIDs on cardiovascular risk and hypertension

COX - 2 Inhibitors , Other NSAIDs , and Cardiovascular Risk

The concept was appealing in its simplicity. Traditional nonsteroidal antiinflammatory drugs (NSAIDs) inhibited both isoforms of the enzyme cyclooxygenase responsible for the first step in the conversion of arachidonic acid into a variety of prostaglandins, thromboxanes, and leukotrienes throughout the body. The anti-inflammatory and pain-relieving effects of NSAIDs resulted from inhibition of ...

Cardiovascular safety of NSAIDs.

Evidence • Meta-analysis of 754 RCTs (about 350 000 patients)1: -Mixed population, primarily patients with arthritis at low to moderate CV risk (ie, CV event rate about 1% per year). -Use of COX-2 inhibitors compared with placebo increased —all-cause mortality, rate ratio (RR) = 1.22 (95% CI 1.04 to 1.44); and —serious CV events, RR = 1.37 (95% CI 1.14 to 1.66). -Diclofenac (150 mg daily): simi...

Cardiovascular Risk of NSAIDs: Time to Translate Knowledge into Practice

Clinical use of non-steroidal anti-inflammatory drugs (NSAIDs) carries cardiovascular risk, which acquires implications for public health against the backdrop of rising chronic disease rates in lowand middleincome countries (LMICs). New evidence from an international study conducted by Patricia McGettigan and David Henry and published this week in PLOS Medicine [1] sheds light on how emerging e...

Risk of gastrointestinal bleeding and cardiovascular events due to NSAIDs in the diabetic elderly population

OBJECTIVE We assessed gastrointestinal bleeding (GIB) and cardiovascular (CV) risks such as myocardial infarction or stroke associated with non-steroidal anti-inflammatory drug (NSAID) use among elderly patients with diabetes. METHODS Using a nationwide claims database covering 2008-2012, we conducted a cohort study of patients with diabetes aged ≥65 years. Among the 117 610 patients, NSAID u...